Results 331 to 340 of about 205,182 (367)

Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia. [PDF]

Biomedicines
Martinez Flores D, Akhoundova D, Seipel K, Legros M, Kronig MN, Daskalakis M, Bacher U, Pabst T.   +7 more
europepmc   +1 more source

Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era. [PDF]

Clin Exp Med
Li Y, Zhang X, Zou Z, Xiong Y, Gu X, Zou R, Tan J, Zhang L, Zheng Y, Niu T.   +9 more
europepmc   +1 more source

High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial. [PDF]

Hemasphere
Manuel G, Stepanishyna Y, Skrypets T, Marcheselli L, Cristinelli C, Botto B, Tonino S, Cavalieri D, Pulsoni A, Hutchings M, Hammoud M, Fortpied C, Rigacci L, Plattel W, André M, Federico M.   +15 more
europepmc   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Autologous stem cell transplantation in scleroderma

La Presse Médicale, 2021
Patients with severe rapidly progressive systemic sclerosis (SSc) have a poor prognosis. Standard immunosuppressive therapies may have modest effects on stabilizing disease, but they fail to improve overall survival. Hematopoietic stem cell transplant (HSCT) is the first treatment to induce disease-modifying therapeutic benefits in rapidly progressive ...
Dominique Farge, Dominique Farge, Zora Marjanovic, Nicoletta Del Papa, Nassim Ait Abdallah   +4 more
openaire   +3 more sources

Autologous Stem Cell Transplantation: Introduction

Seminars in Hematology, 2007
Item does not contain ...
de Witte, T.J.M., de Witte, T.J.M.
openaire   +3 more sources

Autologous Stem Cell Transplantation for T-Cell Lymphomas

Seminars in Hematology, 2014
Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of T-cell malignancies characterized by a very poor outcome. The optimal treatment for PTCLs remains controversial. The role of stem cell transplantation in PTCLs has been investigated; however, no randomized control studies specifically dedicated to PTCLs are currently available ...
Giulia, Perrone, Perrone, Giulia, Paolo, Corradini   +2 more
openaire   +3 more sources

Advances in Autologous Stem Cell Transplantation

Cancer Investigation, 1997
INTRODUCTION In the past 10 years, autologous stem cell transplantation (ASCT) has emerged as a major new form of treatment for a variety of malignant diseases. Indeed, the overall number of autologous transplants registered with the Autologous Blood and Marrow Transplant Registry (ABMTR) in a 5-year period ending in 1994 was 16,561 (1).
Anthony D. Ho, James R. Mason
openaire   +3 more sources

Overview of autologous stem cell transplantation

Critical Reviews in Oncology/Hematology, 2000
There has been a dramatic increase in the number of autologous peripheral blood stem cell transplants over the last decade. Faster recovery of cell counts, lesser transplant morbidity, shorter hospital stay and reduced cost compared with marrow autografts have been the main advantages of autologous peripheral blood cell over marrow transplants. In this
Rick Abraham, Armand Keating, Nabil F. Saba   +2 more
openaire   +2 more sources